Verastem posts November update on AVMAPKI FAKZYNJA and VS-7375 pipeline
The company reported Q3 net product revenue of $24 million and pro forma cash of $422.8 million as it advances Phase 3 trials and a KRAS G12D inhibitor program.
SEC filing
4 stories
The company reported Q3 net product revenue of $24 million and pro forma cash of $422.8 million as it advances Phase 3 trials and a KRAS G12D inhibitor program.
SEC filing
Verastem priced a public offering expected to net about $234.7 million as it named Michael Bailey CEO and reported new VS-7375 pancreatic, colorectal and lung cancer data.
SEC filing (3)